Reduction of visible bone metastases by clodronate therapy in breast cancer.
The current report describes a 57-year-old patient with multiple bone metastases 14 years after her initial treatment for breast cancer. The only therapy the patient received for her osteolytic lesions was oral clodronate (800 mg/daily), as she refused any other kind of treatment. On bone scintigraphy the number of visible bone metastases diminished slowly and after two years only a few minor lesions could be seen. Together with this report the value of oral clodronate as anti-osteolytic therapy in breast cancer patients is discussed.
Tjalma
W A
WA
Department of Obstetrics and Gynecology, University Hospital Antwerp, Belgium. wiebren.tjalma@uza.uia.ac.be
Buytaert
P M
PM
Berneman
Z N
ZN
D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary; D001943:Breast Neoplasms / Q000473:pathology*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000556:secondary; D004002:Clodronic Acid / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D011877:Radionuclide Imaging; D016896:Treatment Outcome
D018712:Analgesics, Non-Narcotic; D000964:Antimetabolites, Antineoplastic; D004002:Clodronic Acid